ReviewFrontiers in immunology2015
Toward Development of iMesenchymal Stem Cells for Immunomodulatory Therapy.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Harnessing MSC Immunomodulation in Orthopedics: Clinical Insights for Comorbidities.Stem cell reviews and reports · 2026Review
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- Therapeutic application of canine adipose tissue-derived mesenchymal stromal cells in a dog with refractory immune-mediated thrombocytopenia, with diabetic ketoacidosis, and gastrointestinal bleeding induced by immunosuppressive treatment.Veterinary research communications · 2025Article
- Immunomodulatory interactions between mesenchymal stromal/stem cells and immune cells in psoriasis: therapeutic potential and challenges.Stem cell research & therapy · 2025Review
- Review
- Mesenchymal stromal cells (MSCs) as a therapeutic agent of inflammatory disease and infectious COVID-19 virus: live or dead mesenchymal?Molecular biology reports · 2024Review
- Stimulated Human Umbilical Cord Mesenchymal Stem Cells Enhance the Osteogenesis and Cranial Bone Regeneration through IL-32 Mediated P38 Signaling Pathway.Stem cells international · 2024Article
- Exploring the therapeutic potential of different sources of mesenchymal stem cells: a novel approach to combat burn wound infections.Frontiers in microbiology · 2024Review
- Regulation of inflammation during wound healing: the function of mesenchymal stem cells and strategies for therapeutic enhancement.Frontiers in pharmacology · 2024Review
- Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke.Human cell · 2024Review
- Substrate topographies modulate the secretory activity of human bone marrow mesenchymal stem cells.Stem cell research & therapy · 2023Article
- Bone regeneration in inflammation with aging and cell-based immunomodulatory therapy.Inflammation and regeneration · 2023Review
- Immunomodulatory Mechanism and Potential Application of Dental Pulp-Derived Stem Cells in Immune-Mediated Diseases.International journal of molecular sciences · 2023Review
- Immunomodulatory Properties of Mouse Mesenchymal Stromal/Stem Cells Upon Ectopic Expression of Immunoregulator Nanos2.Stem cell reviews and reports · 2023Article
- Tumour necrosis factor alpha, interleukin 1 beta and interferon gamma have detrimental effects on equine tenocytes that cannot be rescued by IL-1RA or mesenchymal stromal cell-derived factors.Cell and tissue research · 2023Article
- Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases.Frontiers in pharmacology · 2023Review
- Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges.Stem cells translational medicine · 2022Review
- Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment.Cytotherapy · 2022Review
- Pre-Conditioning with IFN-γ and Hypoxia Enhances the Angiogenic Potential of iPSC-Derived MSC Secretome.Cells · 2022Article
- Optimization of Human Mesenchymal Stem Cells for Rheumatoid Arthritis: Implications for Improved Therapeutic Outcomes.ACR open rheumatology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSC) are under development as an immunomodulatory therapy. The anticipated immunomodulatory effects of MSC are broad, from direct inhibition of lymphocyte proliferation, induction of regulatory T and B cells, to resetting the immune system via a hit-and-run principle. There are endless flavors of MSC. Differences between MSC are originating from donors variation, differences in tissue of origin, the effects of culture conditions, and expansion time. Even standard culture conditions change the properties of MSC dramatically and generate MSC that only remotely resemble their in vivo counterparts. Adjustments in culture protocols can further emphasize properties of interest in MSC, thereby generating cells fitted for specific purposes. Culture improved immunomodulatory MSC can be designed to target particular immune disorders. In this review, we describe the observed and the desired immunomodulatory effects of MSC and propose approaches how MSC with optimal immunomodulatory properties can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.